Biosimilar Development News

  1. Evernorth Announces New Era Of Pharmacy Benefit Services To Lower Americans' Medication Costs 10/27/2025

    Evernorth, the health services division of The Cigna Group (NYSE:CI) today announced a new rebate-free pharmacy benefit model designed to help Americans stay healthy and get the medications they need by lowering costs, improving transparency, and supporting local pharmacies so care is always within reach.

  2. AAM Requests Federal Injunction To Block Connecticut's Unconstitutional Drug Price Law 10/23/2025

    The Association for Accessible Medicines, the trade association representing America’s manufacturers of generic and biosimilar medicines, today filed a preliminary injunction seeking to enjoin enforcement of Connecticut’s new price-control law, Sections 345–347 of Public Act No. 25-168.

  3. Biocon Biologics Receives Health Canada Approval For Yesintek™ And Yesintek™ I.V. (ustekinumab), A Biosimilar To Stelara® 10/23/2025

    Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek™ (ustekinumab injection) and Yesintek™ I.V. (ustekinumab for injection, solution for intravenous infusion), a biosimilar to Stelara® (ustekinumab injection) and Stelara® I.V. (ustekinumab for injection, solution for intravenous infusion).

  4. Alvotech Announces Changes In Global Business Development And Commercial Operations Team 10/22/2025

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its global business development and commercial operations team.

  5. Formycon's FYB201/Ranivisio Sets Innovative Standard As Europe's First Ranibizumab Biosimilar Available In Pre-Filled Syringe 10/21/2025

    Formycon AG (“Formycon”), Bioeq AG (“Bioeq”) and Teva Pharmaceutical Industries Ltd. (“Teva”) jointly announce the European launch of FYB201/Ranivisio as the first Lucentis3 biosimilar available in an EMA-approved innovative pre-filled syringe (“PFS”) presentation.

  6. Polpharma Biologics Announces Commercial Launch Of Europe's First Pre-Filled Syringe Presentation Of A Ranibizumab Biosimilar 10/21/2025

    Polpharma Biologics today announced Ranivisio PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France.

  7. BIOCHINA2026 – Fusion Forward: Uniting The Global Biopharma Community In Suzhou 10/20/2025
  8. Teva And Prestige Biopharma Enter License Agreement For Tuznue® Commercialization In Europe 10/20/2025

    Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets.

  9. Bio Usawa Announces Approval Of BioUcenta™ By The Rwandan FDA 10/20/2025

    The Rwanda Food and Drugs Authority has granted market approval for Bio Usawa Biotechnology Ltd.’s (Bio Usawa) BioUcenta™, a biosimilar of Lucentis® (ranibizumab) for the treatment of diabetic macular edema, age-related macular degeneration and diabetic retinopathy.

  10. FDA Approves Expanded Pediatric Indications For YUFLYMA® (adalimumab-aaty) And Unbranded adalimumab-aaty In The United States 10/17/2025

    Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in adolescent patients aged 12 years and older, and uveitis (UV) in pediatric patients aged 2 years and older.[1],[2]